For example, the identification of IGH::MYC and IGH::BCL2 fusions in Cases 1, 2, and 4 aligns with high-grade DLBCL, which may benefit from intensified regimens or clinical trials targeting MYC or BCL2. This evidence concerns the gene BCL2 and diffuse large B-cell lymphoma.